atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention
Conditions
Interventions
1 month after PCI , dual antiplatelet therapy (DAPT) with VKA plus P2Y12 inhibitor will be performed for 12 months.
1 month after PCI , dual antiplatelet therapy (DAPT) with apixaban plus P2Y12 inhib
Sponsors
Saiseikai Kumamoto Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Atrial fibrillation and Coronary Heart Deseiase(including cases during VKA administration) (2)Patients undergoing coronary angioplasty with drug-eluting stent (3)Patients with informed consent for participation in this study
Exclusion criteria
Exclusion criteria: (1)Case of atrial fibrillation due to reversible cause (2)Patients scheduled for ablation for atrial fibrillation (3)Cases of increased bleeding risk (4)Patients who need anticoagulation other than atrial fibrillation (5)Cerebral infarction within 7 days of onset (6)Infective endocardial inflammation (7)Mitral stenosis case (8)Insufficient control of hypertension (9)Cases scheduled for surgical treatment (10)Hb<9.0g/dl or platelet count 100,000 / mm3 or less case (11)A case with severe liver disorder (12)A case with severe renal injury (13)Patients who are expected to have a life expectancy of less than one year (14)Cases already receiving NOAC (15) Other cases deemed inappropriate by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| major and clinically relevant nonmajor bleeding | — |
Secondary
| Measure | Time frame |
|---|---|
| death, myocardial infarction, stroke, target vessel revascularization(TVR), stent thrombosis | — |
Countries
Japan
Contacts
Public ContactTomohiro Sakamoto
Saiseikai Kumamoto Hospital Cardiology internal medicine
Outcome results
None listed